Table 2. . Summary of selected cardiovascular and renal efficacy outcomes from the CREDENCE trial.

Outcome	Hazard ratio (95% CI) for canagliflozin vs placebo
End-stage kidney disease, doubling of serum creatinine level, or renal or CV death (primary outcome)	0.70 (0.59–0.82)
Doubling of serum creatinine level	0.60 (0.48–0.76)
End-stage kidney disease	0.68 (0.54–0.86)
CV death	0.78 (0.61–1.00)
CV death or hospitalization for HF	0.69 (0.57–0.83)
CV death, nonfatal myocardial infarction or nonfatal stroke	0.80 (0.67–0.95)
Hospitalization for HF	0.61 (0.47–0.80)
End-stage kidney disease, doubling of serum creatinine level or renal death	0.66 (0.53–0.81)
Death from any cause	0.83 (0.68–1.02)

CV: Cardiovascular; HF: Heart failure.